Group 1 - The Hong Kong pharmaceutical sector is experiencing a rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 2% and achieving a trading volume exceeding 2.05 billion yuan, leading its peers with a total scale of over 22.8 billion yuan [1] - The 2026 European Association of Urology (EAU) annual meeting held in London showcased innovative applications of HER2-targeted antibody-drug conjugates (ADCs) in treating urothelial carcinoma, with multiple cutting-edge research results from China presented [3] - Rongchang Biopharmaceutical recently reported a revenue of 3.251 billion yuan, a year-on-year increase of 89.36%, and a net profit of 709 million yuan, marking a turnaround from losses, primarily driven by increased sales of its injectable drugs [3] Group 2 - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its constituent stocks perform positively, with Rongchang Biopharmaceutical up over 6%, Kangzhi Pharmaceutical up over 5%, and China Biopharmaceutical up over 3% [3] - Recent approvals for new drugs and indications in China include: 1) Hengrui Medicine's oral new drug for a new indication; 2) Roche's CD79B ADC new indication approved in China; 3) Kangzhi Pharmaceutical's new drug for renal anemia approved; 4) Junshi Biosciences' first domestic PD-1 subcutaneous formulation submitted for approval [6] - The innovative drug sector in China is transitioning from "fast following" to "innovation leading," with significant advancements in new technology platforms such as molecular glue, small nucleic acids, and in vivo CART, which are expected to enhance drug development efficiency and cost-effectiveness [7][8][9] Group 3 - The recent policy shift designating the biopharmaceutical industry as an emerging pillar industry is expected to release a series of policy dividends, indicating a positive outlook for the sector [11] - The Hong Kong Stock Connect Innovation Drug ETF (159570) is fully invested in innovative drugs, with the top ten constituent stocks accounting for 73.54% of its weight, highlighting its focus on the innovation drug sector [12]